CTOs on the Move

Vor Biopharma

www.vorbio.com

 
Vor Biopharma is pioneering engineered hematopoietic stem cells (eHSCs) to dramatically change the treatment paradigm for hematological cancers. Vor`s eHSCs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. Vor`s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vor`s lead program has been published in ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vorbio.com
  • 100 Cambridgepark Drive Suite 400
    Cambridge, MA USA 02140
  • Phone: 617.655.6580

Executives

Name Title Contact Details
Hunt Grobert
Associate Director, IT Operations & Security Profile
Sadik Kassim
Chief Technology Officer Profile
Sadik Kassim
Chief Technology Officer Profile

Funding

Vor Biopharma raised $42M on 02/14/2019
Vor Biopharma raised $110M on 07/07/2020

Similar Companies

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Totient

Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics.

Aulos Bioscience

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

AuraSense Therapeutics

AuraSense Therapeutics (AST) is a biopharmaceutical company developing first-in-class therapies based upon its proprietary Spherical Nucleic Acid (SNA) gene regulation and immune modulation strategies. AST is leading the translation of SNA constructs as innovative medicines with a core focus on debilitating diseases with limited or no treatment options. AuraSense Therapeutics' uniquely engineered SNA™ constructs possess attractive biocompatibility and versatility as therapeutics and hold great promise for combating the most life-threatening diseases, including many forms of cancer, infectious disease, and skin conditions.

Kronos Bio

Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.